⌘K
t
| Date | 11 Nov 2021 |
| Time | 07:00:04 |
| Category | Corporate updates |
| ID | 0127S |
11 November 2021
Creo Medical Group PLC
("Creo" or the "Company")
Appointment of Joint Broker
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the appointment of Numis as the Company's Joint Broker with immediate effect.
Cenkos Securities plc remains Nominated Adviser and Joint Broker to the Company.
For further information, please contact:
|
Creo Medical Group plc Richard Rees (CFO)
|
+44 (0)1291 606 005 |
|
Cenkos Securities plc Stephen Keys / Camilla Hume (NOMAD) Michael Johnson / Russell Kerr (Sales)
|
+44 (0)20 7397 8900 |
|
Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black / Duncan Monteith
|
+44 (0)20 7260 1000 |
|
Walbrook PR Ltd Paul McManus / Sam Allen Phillip Marriage |
+44 (0)20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Group's three initial areas of focus are (1) in the GI, (2) soft tissue ablation (including but not limited to, the liver, pancreas, kidney) and (3) lung interventions for the resection and/or ablation of pre-cancerous and cancerous lesions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com